secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001831283-22-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing
----------------------------------------------------------------------------

- Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.
- Cash, equivalents, marketable securities $403.2M at Dec 31, 2021; runway through 2023.
- Phase 3 EXPLORER-CN trial of mavacamten initiated in Chinese oHCM patients; Breakthrough Therapy designation granted.
- Infigratinib approved under named patient program for cholangiocarcinoma in Hainan pilot zone.
- Three programs (TP-03, NBTXR3, infigratinib) expected to enter Phase 3 in China by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/0001831283-22-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/lian-20220330.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer